Last reviewed · How we verify
BAY1143572
At a glance
| Generic name | BAY1143572 |
|---|---|
| Sponsor | Bayer |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia (PHASE1)
- Open Label Phase I Dose Escalation Study With BAY1143572 in Patients With Advanced Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- BAY1143572 CI brief — competitive landscape report
- BAY1143572 updates RSS · CI watch RSS
- Bayer portfolio CI